Antisense imaging: where are we now?
The field of antisense targeting is changing rapidly as additional results from in vitro studies and animal and patient trials become available. While these developments apply primarily to antisense chemotherapy, many have implications for antisense imaging and radiotherapy. It may now be profitable to reconsider antisense imaging in the light of these recent developments. With the benefit of further insight, it may be possible to predict which antisense mechanisms will be preferable for antisense imaging. It is also possible to consider the influences of carriers (vectors) on the targeting of antisense DNA and whether this might improve imaging. Furthermore, estimates showing only low mRNA steady-state copy numbers per cell may be reconsidered in refining predictions of tissue counting rates. Finally, recent results suggest that radiolabeling antisense DNAs may not adversely influence the targeting properties of antisense DNAs.
Hnatowich
D J
DJ
Department of Radiology, University of Massachusetts Medical School, Worcester, MA 01655, USA. donald.hnatowich@umass med.edu
D016373:DNA, Antisense / Q000187:drug effects / Q000378:metabolism; D005822:Genetic Vectors / Q000627:therapeutic use; D014176:Protein Biosynthesis / Q000187:drug effects; D012333:RNA, Messenger / Q000378:metabolism; D011877:Radionuclide Imaging / Q000379:methods* / Q000639:trends
D016373:DNA, Antisense; D012333:RNA, Messenger